&lt;p&gt;Comparative Analysis of the Preventive Effects of Canagliflozin, a Sodium-Glucose Co-Transporter-2 Inhibitor, on Body Weight Gain Between Oral Gavage and Dietary Administration by Focusing on Fatty Acid Metabolism&lt;/p&gt;

Kawarasaki, Satoko; Sawazaki, Honami; Iijima, Hiroaki; Ng, Su-Ping; Kwon, Jungin; Mohri, Shinsuke; Iwase, Mari; Jheng, Huei-Fen; Takahashi, Haruya; Nomura, Wataru; Inoue, Kazuo; Kawada, Teruo; Goto, Tsuyoshi

doi:10.2147/dmso.s269916

Cited by 4 publications

(2 citation statements)

References 22 publications

(28 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, this enzyme could be an important biomarker for the detection of liver steatosis [4]. When canagliflozin was administered in mice, Kawarasaki et al demonstrated reduced FAS expression relative to fat mass, resulting in the absence of weight increase [90]. In a 24-week double-blind, placebo-controlled clinical trial, administration of canagliflozin to patients with poorly regulated T2DM demonstrated reduced accumulation of triglycerides within the liver [91].…”

Section: Potential Biomarkers Of Steatosismentioning

confidence: 99%

Biomarkers for Assessing Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus on Sodium–Glucose Cotransporter 2 Inhibitor Therapy

Khaznadar,

Petrovic,

Khaznadar

et al. 2023

JCM

View full text Add to dashboard Cite

In the current modern era of unhealthy lifestyles, non-alcoholic fatty liver disease (NAFLD) is the most prevalent liver disease and has become a serious global health problem. To date, there is no approved pharmacotherapy for the treatment of NAFLD, and necessary lifestyle changes such as weight loss, diet, and exercise are usually not sufficient to manage this disease. Patients with type 2 diabetes mellitus (T2DM) have a significantly higher risk of developing NAFLD and vice versa. Sodium–glucose cotransporter 2 (SGLT2) inhibitors are antidiabetic agents that have recently been approved for two other indications: chronic kidney disease and heart failure in diabetics and non-diabetics. They are also emerging as promising new agents for NAFLD treatment, as they have shown beneficial effects on hepatic inflammation, steatosis, and fibrosis. Studies in animals have reported favorable effects of SGLT2 inhibitors, and studies in patients also found positive effects on body mass index (BMI), insulin resistance, glucose levels, liver enzymes, apoptosis, and transcription factors. There are some theories regarding how SGLT2 inhibitors affect the liver, but the exact mechanism is not yet fully understood. Therefore, biomarkers to evaluate underlying mechanisms of action of SGLT2 inhibitors on the liver have now been scrutinized to assess their potential as a future in-label therapy for NAFLD. In addition, finding suitable non-invasive biomarkers could be helpful in clinical practice for the early detection of NAFLD in patients. This is crucial for a positive disease outcome. The aim of this review is to provide an overview of the most recent findings on the effects of SGLT2 inhibitors on NAFLD biomarkers and the potential of SGLT2 inhibitors to successfully treat NAFLD.

show abstract

Section: Potential Biomarkers Of Steatosismentioning

confidence: 99%

Biomarkers for Assessing Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus on Sodium–Glucose Cotransporter 2 Inhibitor Therapy

Khaznadar,

Petrovic,

Khaznadar

et al. 2023

JCM

View full text Add to dashboard Cite

show abstract

“…SGLT2 is also known to play an important role in fatty acid metabolism [ 4 ]. The liver is the central organ involved in fatty acid metabolism.…”

Section: Introductionmentioning

confidence: 99%

Hepatic expression of sodium–glucose cotransporter 2 (SGLT2) in patients with chronic liver disease

et al. 2022

View full text Add to dashboard Cite

Sodium–glucose cotransporter 2 (SGLT2) occurs in the proximal renal tubule cells. We investigate the hepatic expression of SGLT2 and its related factors in patients with chronic liver disease. This is a retrospective human study. The liver tissues were biopsied from patients with chronic liver disease (n = 30). The expression levels of SGLT2 were evaluated by immunostaining. Furthermore, the undirected graphical model was used to identify factors associated with hepatic expression levels of SGLT2. The SGLT2 expression was observed in not only the kidney, but also the liver in immunostaining (SGLT2 intensity: kidney 165.8 ± 15.6, liver 114.4 ± 49.0 arbitrary units, P < 0.01) and immunoblotting. There was no significant difference in hepatic expression of SGLT2 in the stratified analysis according to age, sex, BMI, and the severity of the liver disease. In the undirected graphical model, SGLT2 directly interacted with various factors such as sex, fatty change, neutrophil-to-lymphocyte ratio, triglyceride, hemoglobin A1c, creatinine, and albumin (partial correlation coefficient 0.4–0.6 for sex and 0.2–0.4 for others). The expression of SGLT2 was observed in the hepatocytes of patients with chronic liver disease. The undirected graphical model demonstrated the complex interaction of hepatic expression levels of SGLT2 with gender, inflammation, renal function, and lipid/glucose/protein metabolisms.

show abstract

Long-term effects of canagliflozin treatment on the skeleton of aged UM-HET3 mice

et al. 2023

View full text Add to dashboard Cite

<p>Comparative Analysis of the Preventive Effects of Canagliflozin, a Sodium-Glucose Co-Transporter-2 Inhibitor, on Body Weight Gain Between Oral Gavage and Dietary Administration by Focusing on Fatty Acid Metabolism</p>

Cited by 4 publications

References 22 publications

Biomarkers for Assessing Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus on Sodium–Glucose Cotransporter 2 Inhibitor Therapy

Biomarkers for Assessing Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus on Sodium–Glucose Cotransporter 2 Inhibitor Therapy

Hepatic expression of sodium–glucose cotransporter 2 (SGLT2) in patients with chronic liver disease

Long-term effects of canagliflozin treatment on the skeleton of aged UM-HET3 mice

Contact Info

Product

Resources

About